A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (Q82837990)
Jump to navigation
Jump to search
scientific article published on 06 December 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis |
scientific article published on 06 December 2011 |
Statements
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (English)
Michael Yellin
Andra Balanescu
Semen Ter-Vartanian
Vira Tseluyko
Li-An Xu
Xiaolu Tao
Pina M Cardarelli
Heidi Leblanc
Geoff Nichol
Rodica Chirieac
6 December 2011